BMS' Chief Medical Officer Is Cultivating a Patients-First Environment

Samit Hirawat, MD joined Bristol-Myers Squibb in June 2019 as Chief Medical Officer, Global Drug Development.  Dr Hirawat is a highly collaborative leader who brings extensive drug development experience to the role. Prior to joining Bristol-Myers Squibb, Dr Hirawat most recently served as Executive Vice President and Head of Oncology Global Development at Novartis. Dr Hirawat also led clinical development programs in multiple indications at PTC Therapeutics and Pfizer/Pharmacia Corporation.Dr Hirawat received his Bachelor of Medicine and Bachelor of Surgery (MB; BS) from the Sawai Man Singh Medical College in India, and completed his Internal Medicine Residency and Medical Oncology Training at North Shore University Hospital, New York. He is an author of several manuscripts and abstracts published in peer-reviewed journals and presented at major conferences. Dr Hirawat is a recipient of several government grants, academic and corporate awards.

Sarah Krüg is the founder of the Health Collaboratory, a global innovation hub that paves the path for participatory co-design and collaboration in healthcare, with a focus on amplifying the voice of the patient and care/support partner in the design, development and continuous improvement of healthcare innovations. The Health Collaboratory has launched various innovations such as Prescription to Learn®, a Health GPS, and the Patient Shark Tank®, among others. Through the Patient Shark Tank ®, over 19,000 patients and care/support partners across disease states have evaluated innovations across the globe, including technology, education, research, and policy. Ms Krüg is the CEO of CANCER101, a patient advocacy organization whose mission is to help patients and care/support partners navigate the cancer journey and partner with their healthcare team to make informed decisions. She is also the Acting Executive Director and Past President of the Society for Participatory Medicine, a patient: clinician member driven organization, whose mission is to enable collaborative partnerships between patients and healthcare professionals. She serves on the board of the National Organization for Rare Disorders.  Ms Krüg is also the author of “A Roadmap to Wellness”.She previously held the position of Global Education Director as well as Patient Advocacy Lead at Pfizer. She also established the Global Investigator Initiated Research Program at Pfizer.  Prior to joining Pfizer, Ms Krüg spearheaded the development of the Disease Management Clinical Pathways and conducted clinical research at Memorial Sloan- Kettering Cancer Center.